Business
Castle Biosciences Presents Data from Suite of Dermatologic Cancer Genomic Tests at Fall Clinical Dermatology Conference 2021
The Company also highlights the study design for its pipeline program to predict response to systemic therapeutics in patients diagnosed with moderate to
About this update from Castle Biosciences, Inc.
[{"type":"text","content":"\nThe Company also highlights the study design for its pipeline program to predict response to systemic therapeutics in patients diagnosed with moderate to severe inflammatory dermatologic conditions\n\n FRIENDSWOOD, Texas--(BUSINESS WIRE)--\nCastle Biosciences, Inc. (Nasdaq: CSTL), applying innovative diagnostics to transform disease management and improve patient outcomes, today announced recent poster presentations on the Company’s suite of dermatologic cancer gene expression profile (GEP) tests, as well as a poster describing the study design for its inflammatory skin disease pipeline initiative at the 2021 Fall Clinical Dermatology Conference, held Oct. 21-24.\n\nDecisionDx®-Melanoma:\n\nDecisionDx-Melanoma is Castle’s prognostic gene expression profile test for cutaneous melanoma. The Company utilizes two proprietary algorithms, i31-ROR and i31-SLNB, to produce an integrated test result designed to provide a precise, personalized prediction of risk of recurrence and likelihood of sentinel lymph node (SLN) positivity, respectively, by integrating DecisionDx-Melanoma with traditional assessment of the clinicopathologic features of a patient’s tumor.\n\nThe company presented new data on the capabilities of these independently validated algorithms through a poster titled, “Integrating the 31-gene expression profile and clinicopathologic data to determine the risk of sentinel lymph node positivity and recurrence-free survival in cutaneous melanoma.” The poster can be found here.\n\n“The risks associated with a melanoma diagnosis can lead to several different clinical procedures, including sentinel lymph node biopsy (SLNB), and many patients experience regional recurrence, distant metastasis or even death,” said Bob Cook, Ph.D., senior vice president of research and development of Castle Biosciences. “The study results demonstrated that integrating the DecisionDx-Melanoma result with assessment of clinical and pathologic features improved individualized risk prediction for SLNB positivity, regional recurrence and distant metastasis, which could help clinicians make more informed and personalized risk-stratification decisions.”\n\nStudy methods and findings:\n\n\nThe purpose of the study was to demonstrate the combined ability of two independently validated algorithms that incorporate the DecisionDx-Melanoma result with clinicopa...